Targeting the ALK gene with the oral agent crizotinib (Xalkori) slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, anaplastic large cell lymphoma ...
NICE, the healthcare guidance body, has issued final guidance not recommending crizotinib (Xalkori, Pfizer) for previously treated anaplastic-lymphoma-kinase-positive advanced non-small-cell lung ...
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group Before anaplastic lymphoma kinase (ALK) inhibitors, treatment ...
(HealthDay News) – For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase (ALK) gene, crizotinib is well tolerated and has antitumor activity, according to ...
"As with ALK-positive lung cancer, ROS1-positive lung cancer defines a distinct subset of patients for whom crizotinib is efficacious." Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and ...
(Reuters) - Japan's biggest drugmaker, Takeda Pharmaceutical Co Ltd, said long-term data show better outcomes for its Alunbrig drug in certain lung cancer patients compared to an existing treatment.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug ...
The researchers found that the rate of progression-free survival was higher with brigatinib compared with crizotinib (estimated 12-month progression-free survival, 67% vs 43%; hazard ratio for disease ...
A new study reports how tracking the evolution of resistance in serial biopsies revealed the molecular mechanisms by which a patient with metastatic non-small-cell lung cancer became resensitized to ...
There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...
CHICAGO -- Five-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena) progression-free survival (PFS) benefit in ALK-positive non-small cell lung cancer (NSCLC). In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results